Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 3 2Phase 1 2Phase 2 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Classical hematology 1

Conditions

Venous Thromboembolism 1Ovarian Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 624pembrolizumab 500Paclitaxel 456Gemcitabine 438Carboplatin 435Cisplatin 418Radiotherapy 380fludarabine 365Nivolumab 340Docetaxel 277Bevacizumab 276Irinotecan 257Magnetic Resonance Spectroscopy 242Fluorouracil 228Dexamethasone 225Specimen Handling 221Capecitabine 218Rituximab 205Cytarabine 201Oxaliplatin 200Ipilimumab 199Temozolomide 197Biopsy 196fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 173Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Fondaparinux × Clear all
NCT00659399 2015-03-18

Feasibility Study of Short Term Fondaparinux (Arixtra) in Chemotherapy-Pretreated Ovarian Carcinoma Patients at High Risk of Progression

NYU Langone Health

Phase 1 Withdrawn
Gynecologic

Ovarian Neoplasms

NCT00476216 2014-03-05

Fondaparinux (Arixtra) With Chemotherapy for Advanced Non-Small Cell Lung Cancer

University of Alabama at Birmingham

Phase 1 Completed
23 enrolled
Classical hematologyThoracic

Carcinoma, Non-Small-Cell Lung, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡